Table 1.
HTA reports analyzed
| NICE (GB) |
ICER (US) |
CADTH (CA) |
SMC (GB) |
AIFA (IT) |
HAS (FR) |
G-BA (DE) |
AEMPS (ES) |
|
|---|---|---|---|---|---|---|---|---|
| Kymriah DLBCL | X | X | X | X | X | X | ||
| Kymriah ALL | X | X | X | X | X | X | ||
| Yescarta | X | X | X | X | X | X | X | |
| Luxturna | X | X | X | X | X | X | X | |
| Strimvelis | X | |||||||
| Imlygic | X | X | X | |||||
| Alofisel | X | X | X | X | ||||
| Provenge | X | X | ||||||
| Glybera | X | X | ||||||
| Zolgensma | X | X | X | X | X | X | X |
Key: AEMPS Agencia Española de Medicamentos y Productos Sanitarios, AIFA Agenzia Italiana del Farmaco, ALL acute lymphoblastic leukemia, CADTH Canadian Agency for Drugs and Technologies in Health, DLBCL diffuse large B-cell lymphoma, G-BA Gemeinsamer Bundesausschuss, HAS Haute Autorité de Santé, ICER Institute for Clinical and Economic Review, NICE National Institute for Health and Clinical Excellence, SMC Scottish Medicines Consortium